Wanbury Limited Q3 FY26: PAT Explodes 1,194% YoY to ₹15.8 Cr, Revenue Up 22%

Pharmaceutical major Wanbury Ltd, active in global APIs and domestic formulations, reported stellar Q3 & 9M FY26 results ended December 31, 2025.

Q3 revenue from operations reached ₹162.4 crore, up 21.7% YoY from ₹133.5 crore, driven by higher API volumes, improved capacity utilization, and steady formulations performance. EBITDA (incl. other income) surged 81.7% to ₹26.9 crore (16.5% margin vs 11.0%). PAT skyrocketed 1,194% to ₹15.8 crore (9.7% margin vs 0.9%).

9M FY26 revenue grew 13.6% to ₹485.7 crore, EBITDA rose 60.6% to ₹77.6 crore (16.0% margin), and PAT jumped 332% to ₹44.4 crore (9.1% margin).

Director Mohan Rayana said, "Q3 revenue up 22% YoY, 9M up 14% led by API volumes and formulations growth. EBITDA surged 82% Q3/61% 9M from high-margin SKUs, better yields, solvent recovery, procurement. PAT growth from operations and lower finance costs."

API highlights include commercial launch of high-potent anaesthetic API to Europe from Tanuku facility, with pipeline featuring antidiabetic, anticoagulant, cough suppressant, antidepressant products.

Formulations turned EBITDA positive with success of C-Red nutritional supplement and expansion into new therapeutic categories.

Wanbury's margin expansion and product diversification fuel profitable growth trajectory.

Shares of Wanbury Limited was last trading in BSE at Rs. 243.80 as compared to the previous close of Rs. 261.70. The total number of shares traded during the day was 22792 in over 601 trades.

The stock hit an intraday high of Rs. 261.95 and intraday low of 240.65. The net turnover during the day was Rs. 5672407.00.

Source : Equity Bulls

Keywords

Wanbury INE107F01022 Pharmaceuticals Q3FY26 Q3FY2026 9MFY26 9MFY2026 ResultUpdate